A month has gone by since the last earnings report for AbbVie (ABBV) . Shares have added about 6.1% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.Q4 Earnings & Sales BeatAbbVie reported fourth-quarter 2025 adjuste ...

Key Takeaways AbbVie's neuroscience segment generated $10.8B in 2025 revenue, rising nearly 20% year over year.ABBV saw double-digit growth from Botox Therapeutic, Vraylar, Qulipta and Ubrelvy, with Vyalev adding $482M.ABBV expects $12.5B neuroscience sales in 2026 and aims for Vyalev to surpass $1B in global revenues.AbbVie (ABBV) reported encouraging fourth-quarter and full-year 2025 results last month. While the company’s immunology portfolio accounted for the bulk of revenue growth, its neuroscience fra ...

股票研究 /[Table_Date] 2026.03.05 月度创新药前沿跟踪 2026 年 2 月 [Table_Industry] 医药 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 余克清(分析师) | 010-56760093 | yukeqing@gtht.com | S0880525120002 | | 陈铭(分析师) | 021-23219164 | chenming7@gtht.com | S0880525100004 | | 廖博闻(研究助理) | 021-23187268 | liaobowen@gtht.com | S0880125042239 | 本报告导读： 本报告为全球创新药前沿的月度跟踪报告，梳理和提示了相关前沿领域的进展和投 资机会。 投资要点： [Table_Invest] 评级： 增持 [Table_Report] 相关报告 医药《持续推荐创新药械产业链》20 ...

Group 1 - The core focus of the presentation is on AbbVie's outlook, commercialized products, and ongoing research and development (R&D) efforts [1][2] - AbbVie is expected to gain recognition for its advancements in R&D, which could significantly drive future growth potential [2]

AbbVie FY Conference Summary Company Overview - **Company**: AbbVie (NYSE: ABBV) - **Date of Conference**: March 03, 2026 - **Key Management Present**: - Scott Rents, Executive Vice President and CFO - Jeff Stewart, Executive Vice President and Chief Commercial Officer - Roopal Thakkar, Executive Vice President, R&D, and CSO Core Industry Insights - **Immunology Trials**: AbbVie is successfully conducting immunology trials, unlike some competitors facing high placebo rates. The company attributes its success to high efficacy levels of its assets, such as HUMIRA, SKYRIZI, and RINVOQ [2][3] - **Clinical Trial Strategy**: AbbVie employs rigorous patient and endpoint selection, real-time data monitoring, and training for trial sites to ensure successful outcomes [4][5][6] Key Product Developments - **RINVOQ**: Demonstrated a doubling of response rates compared to HUMIRA in rheumatoid arthritis trials, indicating strong efficacy [5] - **SKYRIZI**: New subcutaneous induction trial for Crohn's disease showed higher efficacy than the IV version, with a 60% endoscopic response in treatment-naive patients [6] - **Lutikizumab**: Undergoing phase 3 trials for hidradenitis suppurativa (HS) with a focus on stringent endpoints to control placebo responses [7][9] Market Potential - **Hidradenitis Suppurativa**: Identified as an under-penetrated market with significant growth potential, similar to inflammatory bowel disease (IBD) [13] - **Long-term Growth Outlook**: AbbVie projects a high single-digit CAGR from 2024 to 2029, with continued EPS expansion and a strong pipeline in immunology, oncology, and neuroscience [25][26] Pipeline and Future Strategies - **Immunology Pipeline**: Focus on B-cell depletion strategies and combination therapies to reset the standard of care in rheumatologic diseases [30][32] - **Neuroscience**: Anticipation of tavapadone approval, which is expected to complement existing therapies and capture significant market share [41] - **Oncology**: Development of antibody-drug conjugates (ADCs) for various cancers, with promising data from ongoing trials [34][38] Financial Outlook - **Investment in R&D**: AbbVie has increased R&D spending significantly, with plans to continue investing in pipeline development [26][28] - **BOTOX**: Continues to be a major asset with a strong market presence, particularly in aesthetics and therapeutics [50] Additional Insights - **Regulatory Strategy**: AbbVie is adapting to new trial policies to enhance efficiency and speed in clinical studies [14] - **Market Positioning**: The company is well-positioned to capitalize on its diverse portfolio and emerging therapies, with a focus on maintaining a competitive edge in the market [52][53] This summary encapsulates the key points discussed during the AbbVie FY Conference, highlighting the company's strategic focus, product developments, and market outlook.

Macro Trading Factory is a macro-driven service, run by a team of experienced investment managers.The service offers two portfolios: “Funds Macro Portfolio” & “Rose's Income Garden”; both aim to outperform the SPY on a risk-adjusted basis, in a relaxed manner.Suitable for those who either have little time/knowledge/desire to manage a portfolio on their own, and/or wish to get exposed to the market in a simple, though more risk-oriented (less volatile), way.Each of our portfolios, spanning across all sectors ...

In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo1 These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients1 The safety profile of risankizumab SC induction was consistent with its known profile in Crohn's disease, wi ...

We’re a father-and-son team dedicated to helping individual investors achieve financial independence through strategic dividend investing. With years of combined experience and a deep understanding of the markets, we’ve developed a straightforward yet powerful method that empowers investors like you to take control of your financial future, create a massive dividend snowball, and retire happy and free. At The Dividend Freedom Tribe, we don’t serve institutional clients or cater to Wall Street’s elite. Inste ...

AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23, AbbVie (NYSE: ABBV) announced plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities. The new state-of-the-art facilities at the Illinois campus are to integrate advanced manufacturing technologies with artificial intelligence. Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? Artificial intelligence integration is part of AbbVie’s push to support and ...

Core Insights - The Dividend Aristocrats are experiencing a strong start to 2026, with the ProShares S&P 500 Dividend Aristocrat ETF (NOBL) increasing by 5.67% in January [1] Group 1: Performance Metrics - The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) has shown a positive performance trend, indicating strong investor interest and confidence in dividend-paying stocks [1]